FDA Grants 510(k) Clearance to Angiodynamics’ AlphaVac F1885 System for PE Treatment
AngioDynamics has received FDA clearance for the AlphaVac F1885 System to treat pulmonary embolism (PE), a life-threatening condition. PE...
Allurion Bridges Digital Gap, Introduces Virtual Care Suite in US
Allurion Technologies has launched its Virtual Care Suite (VCS) in the United States. It provides a comprehensive weight loss...
EC Approves Bristol Myers’ Reblozyl as First-Line Treatment for LR-MDS Anemia
The European Commission (EC) has expanded approval of Reblozyl (luspatercept), a first-in-class treatment for patients with disease-related anemia, for...
D&D Pharmatech Receives Fast Track Designation from FDA for DD01 – Novel Treatment for NASH/MASH
D&D Pharmatech, a biotech company, has been granted Fast Track designation by the US Food and Drug Administration (FDA)...
EMA Accepts Rocket Pharma’s RP-L102 Application for Fanconi Anemia Treatment
Rocket Pharmaceuticals, a late-stage biotechnology company, has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization...
US FDA Accepts Astrazeneca License Application for Datopotamab Deruxtecan in Metastatic HR+, HER2- Breast Cancer
Biopharmaceutical companies AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted in the US,...
VBI Vaccines Boosts Strategic Partnership to Propel MRNA-Launched EVLP Vaccine Platform
Biopharmaceutical firm VBI Vaccines has expanded its collaboration with the Canadian government, with the latter contributing the remaining CAD$28...
QLS-111 by Qlaris Bio Enters Phase II Trials for IOP Reduction
Qlaris Bio, Inc., a biotechnology firm focusing on ophthalmic diseases, has announced the initiation of two Phase II clinical...
Mirum’s Livmarli Gets Positive CADTH Reimbursement Nod for Alagille Syndrome in Canada
The Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive...
MRD Testing Market Analysis 2024: Revolution in Cancer Management Drives Growth
The MRD (Minimal Residual Disease) testing market is experiencing substantial growth, with its value projected to increase from $1.67...